Centessa Pharmaceuticals PLC (CNTA) intrinsic value & 10-year financials
Centessa Pharmaceuticals PLC (CNTA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 48.0% a year to $15.0M, with an average return on invested capital of 601.4%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $15.0M
- Revenue growth (8-yr CAGR)
- 48.0%
- ROIC (10-yr avg)
- 601.4%
- Free cash flow (FY2025)
- -$194.2M
CNTA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $15.0M | -$197.5M | -$1.46 | -$194.2M | -1384.6% | -57.8% |
| FY2024 | $0 | -$235.8M | -$2.06 | -$142.1M | — | -122.5% |
| FY2023 | $6.9M | -$151.1M | -$1.57 | -$160.5M | -2499.4% | -143.2% |
| FY2022 | $0 | -$216.2M | -$2.31 | -$201.7M | — | 2728.9% |
| FY2021 | — | — | — | — | — | — |
| FY2020 | — | -$10.7M | — | -$10.6M | — | — |
| FY2019 | — | -$5.1M | — | -$5.8M | — | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Centessa Pharmaceuticals plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Centessa Pharmaceuticals plc has historically struggled to out-earn its cost of capital, averaging just -74.1% ROIC.
Centessa Pharmaceuticals plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Centessa Pharmaceuticals plc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-48.49 per share.